MK-2206
| CAS No. | 1032349-93-1 | Cat. No. | BCP20200 |
| Name | MK-2206 | ||
| Synonyms | MK 2206;MK2206; | ||
| Formula | C25H21N5O | M. Wt | 407.48 |
| Description | MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. It is also an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. It has potential antineoplastic activity. It exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models. It induces G1-phase cell cycle arrest in hepatocellular carcinoma cells, inhibits cell proliferation in non-small cell lung cancer cells, and inhibits proliferation in medullary thyroid cancer cells. It also inhibits tumor growth in animal models of nasopharyngeal cancer. | ||
| Related Products | 1032350-13-2（MK-2206 2HCl） | ||
| Pathways | PI3K/Akt/mTOR | ||
| Targets | AKT | ||
|
Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
Publications Citing of Biochempartner's MK-2206(CAS:1032349-93-1) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.